Intellia CEO John Leonard on In Vivo CRISPR Gene-Editing Commercial Launch
Oct 8, 2026
With its first FDA approval approaching, the CRISPR gene-editing company must consider patient adoption, liver safety, and its pipeline’s future.
Read More –Age-Based Genetic Testing Misses 72% of Patients with Inherited Cancer Variants
Oct 8, 2026Glioblastoma Drug Uses Unexpected Mechanism
Oct 7, 2026Chemotherapy Can Boost Cancer Vaccines via T Cells
Oct 7, 2026Patient-Derived GBM Organoid Platform Probes Radiation and Drug Responses
Oct 7, 2026tRNA Influences If Prostate Cancer Becomes Resistant to Treatment
Oct 7, 2026Enzyme Biomarker May Predict CDK4/6 Inhibitor Resistance in Breast Cancer
Oct 7, 2026Gut Microbes Implicated in Post-Vaccination Fever
Oct 8, 2026
HPV Vaccination Prevents Major Pregnancy Complications
Oct 7, 2026
Optogenetic Therapy Shows Early Promise for Retinitis Pigmentosa-Associated Blindness
Oct 7, 2026
Microglia Can ‘Nibble Away’ Toxic Proteins to Protect Neurons in Parkinson’s Disease
Oct 7, 2026
Mitochondria Closely Linked with Cancer Progression
Oct 7, 2026
Statin Use Linked to Lower Glaucoma Risk and Less Need for Intensive Treatment
Oct 6, 2026
News & Features
Gene-Edited CAR T Expands Rare Disease Horizons
August 01, 2026Combining CAR T with CRISPR or TALEN is enabling more precise, scalable cell therapies for autoimmune, fibrotic, and genetic disorders.
From Mila to Many: Making Ultra-Rare Disease Therapies More Accessible
August 01, 2026Newer options like the therapies being developed by Forster and colleagues at Nerai Biosciences, alongside others like potentially curative gene therapies, are on the horizon…
Drug Repurposing’s Next Challenge: Turning Discoveries Into Treatments
August 01, 2026The U.S. Food and Drug Administration (FDA) is now actively involving patients, researchers, and clinicians in efforts to prioritize drug repurposing in areas where commercial…
Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive NSCLC Biomarker Detection in Research Workflows
In this IPM webinar, two experts will discuss the growing role of ddPCR in clinical research and translational oncology.
Surbhi Jain, PhD, MBBS
Staff Scientist
Bio-Rad Laboratories
Prithwish Pal, PhD
Director, Global Product Marketing – Oncology
Bio-Rad Laboratories
Whole Genome Sequencing Diagnoses 47% Neurological Pediatric Cases
Oct 5, 2026Research shows rapid whole genome sequencing can give a diagnosis to many children with unknown neurological symptoms, with better results in older children than in…
Riaan’s Therapeutic Odyssey – Chapter 5: The Family
Oct 1, 2026In the final installment of this series, Riaan and his family face the unknown after five years of developing a genetic medicine for Cockayne syndrome.
Asthma Biologic Interacts with Common Genetic Variant in Children
Oct 1, 2026The frequently used biologic drug mepolizumab may cause an exaggerated inflammatory response in children with severe asthma who carry an incredibly common genetic variant when…
Podcast Series
Behind the Breakthroughs
Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine, as he uncovers the stories behind the pioneers driving the precision medicine revolution.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter.
